Bevacizumab in the treatment of HER2-negative breast cancer.
about
Fatty acid-binding protein 5 and PPARbeta/delta are critical mediators of epidermal growth factor receptor-induced carcinoma cell growthNumerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data.
P2860
Bevacizumab in the treatment of HER2-negative breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bevacizumab in the treatment of HER2-negative breast cancer.
@en
Bevacizumab in the treatment of HER2-negative breast cancer.
@nl
type
label
Bevacizumab in the treatment of HER2-negative breast cancer.
@en
Bevacizumab in the treatment of HER2-negative breast cancer.
@nl
prefLabel
Bevacizumab in the treatment of HER2-negative breast cancer.
@en
Bevacizumab in the treatment of HER2-negative breast cancer.
@nl
P2860
P356
P1476
Bevacizumab in the treatment of HER2-negative breast cancer.
@en
P2093
Vito Lorusso
P2860
P304
P356
10.2147/BTT.S3515
P577
2008-12-01T00:00:00Z